Click here for more information
To receive your instant CME certificate, you must first “Sign In” or “Sign Up” in the top right corner.
MAXIMUM CREDITS: 1.5 AMA PRA Category 1 Credits™
PROCEED TO CME ACTIVITY: CLICK HERE
By the year 2030, approximately half of all Americans will have diabetes. At the time of diagnosis, approximately 20% to 30% of people with diabetes will have some form of nonproliferative diabetic retinopathy. After 25 years living with diabetes, up to 83% of people with nonproliferative diabetic retinopathy will progress to proliferative diabetic retinopathy, which is vision threatening. Nonproliferative diabetic retinopathy can also progress to vision-threatening, center-involved diabetic macular edema. Until recently, treatment options for nonproliferative diabetic retinopathy were limited to laser photocoagulation or anti–vascular endothelial growth factor injection if diabetic macular edema was also present. Accumulating evidence shows that approximately 40% of patients with untreated nonproliferative diabetic retinopathy will develop proliferative diabetic retinopathy or center-involved diabetic macular edema within 1 year, but treatment at this stage of disease can drastically reduce the risk. Whether patients benefit more from laser or anti–vascular endothelial growth factor treatment depends on factors unique to individuals, and communication of modifiable risk factors and discussion of individual patient needs is critical for sight preservation. The desired results of this activity are for retina specialists to gain the knowledge and competence needed to help patients with nonproliferative diabetic retinopathy prevent loss of vision from proliferative diabetic retinopathy and diabetic macular edema.
This educational activity is intended for retina specialists and other ophthalmologists caring for patients with diabetic retinopathy.
Upon completion of this activity, participants will be better able to:
• Analyze the evidence supporting treatment for preventing vision-threatening outcomes in diabetic retinopathy
• Examine clinical trial data supporting treatment of nonproliferative diabetic retinopathy to prevent diabetic retinopathy progression and diabetic macular edema
• Design treatment plans for diabetic retinopathy that consider individual patient factors
• Identify information that should be shared with patients with diabetic retinopathy to help them prevent vision loss
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of New York Eye and Ear Infirmary of Mount Sinai and MedEdicus LLC. The New York Eye and Ear Infirmary of Mount Sinai is accredited by the ACCME to provide continuing medical education for physicians.
AMA CREDIT DESIGNATION STATEMENT
The New York Eye and Ear Infirmary of Mount Sinai designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This continuing medical education activity is supported through an unrestricted educational grant from Regeneron Pharmaceuticals, Inc.
DISCLOSURE POLICY STATEMENT
It is the policy of New York Eye and Ear Infirmary of Mount Sinai that the faculty and anyone in a position to control activity content disclose any real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s). New York Eye and Ear Infirmary of Mount Sinai has established policies in place that will identify and resolve all conflicts of interest prior to this educational activity. Full disclosure of faculty/planners and their commercial relationships, if any, follows.
Nancy M. Holekamp, MD, had a financial agreement or affiliation during the past
year with the following commercial interests in the form of Receipt of Intellectual Rights/Patent Holder: Katalyst Healthcares & Life Sciences; Consultant/Advisory Board: Allegro Ophthalmics, LLC; Allergan; BioTime, Inc; Clearside Biomedical, Inc; Gemini Therapeutics; Genentech, Inc; Novartis Pharmaceuticals Corporation; and Regeneron Pharmaceuticals, Inc; Contracted Research: Alimera Sciences; and Genentech, Inc; Honoraria from promotional, advertising or non-CME services received directly from commercial interests or their Agents (eg, Speakers Bureaus): Alimera Sciences; Allergan; Genentech, Inc; Regeneron Pharmaceuticals, Inc; and Spark; Ownership Interest (Stock options, or other holdings, excluding diversified mutual funds): Katalyst Healthcares & Life Sciences.
Jaclyn L. Kovach, MD, has no relevant commercial relationships to disclose.
Eleonora Lad, MD, PhD, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Apellis Pharmaceuticals; F. Hoffman-La Roche Ltd; Galimedix Therapeutics, Inc; and Novartis Pharmaceuticals Corporation; Contracted Research: Apellis Pharmaceuticals; F. Hoffman-La Roche Ltd; and Novartis Pharmaceuticals Corporation.
Jennifer I. Lim, MD, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: EyePoint Pharmaceuticals; Genentech, Inc; and Kodiak Sciences Inc; Contracted Research: Chengdu Kanghong Pharmaceuticals Group Co, Ltd; Clearside Biomedical, Inc; Genentech, Inc; Janssen Global Services, LLC; Ohr Pharmaceutical; Regeneron Pharmaceuticals, Inc; and Second Sight; Honoraria from promotional, advertising or non-CME services received directly from commercial interests or their Agents (eg, Speakers Bureaus): Genentech, Inc; Other (Data Monitoring Committee Board): Opthea; Quark; and Santen Inc.
NEW YORK EYE AND EAR INFIRMARY OF MOUNT SINAI
PEER REVIEW DISCLOSURE
Gennady Landa, MD, has no relevant commercial relationships to disclose.
EDITORIAL SUPPORT DISCLOSURES
Erika Langsfeld, PhD; Cynthia Tornallyay, RD, MBA, CHCP; Kimberly Corbin, CHCP; Barbara Aubel; and Michelle Ong have no relevant commercial relationships to disclose.
The contributing physicians listed above have attested to the following:
1) that the relationships/affiliations noted will not bias or otherwise influence their involvement in this activity;
2) that practice recommendations given relevant to the companies with whom they
have relationships/affiliations will be supported by the best available evidence or,
absent evidence, will be consistent with generally accepted medical practice; and
3) that all reasonable clinical alternatives will be discussed when making practice recommendations.
This CME activity includes discussion of unlabeled and/or investigative uses of drugs. Please refer to the official prescribing information for each drug discussed in this activity for FDA-approved dosing, indications, and warnings.
NEW YORK EYE AND EAR INFIRMARY OF MOUNT SINAI PRIVACY & CONFIDENTIALITY POLICIES
CME PROVIDER CONTACT INFORMATION
For questions about this activity, call 212-870-8127.
TO OBTAIN AMA PRA CATEGORY 1 CREDIT™
To obtain AMA PRA Category 1 Credit™ for this activity, read the material in its entirety and consult referenced sources as necessary. Please take this post test and evaluation online by going to https://tinyurl.com/preventvisionloss. Upon passing, you will receive your certificate immediately. You must score 70% or higher to receive credit for this activity, and may take the test up to 2 times. Upon registering and successfully completing the post test, your certificate will be made available online and you can print it or file it.
The views and opinions expressed in this educational activity are those of the faculty
and do not necessarily represent the views of New York Eye and Ear Infirmary of
Mount Sinai; MedEdicus LLC; Regeneron Pharmaceuticals, Inc; EyeNet; or the
American Academy of Ophthalmology.
This CME activity is copyrighted to MedEdicus LLC ©2019. All rights reserved. 184
Click here for more information